ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 4999-5009

  Berhanu, Aklile ^a   King, David S ^a   Mosier, Stacie ^a   Jordan, Robert ^a   Jones, Kevin F ^a   Hruby, Dennis E ^a   Grosenbach, Douglas W ^a  

^a SIGA Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ST 246; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL INFECTION; FEMALE; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INOCULATION; LETHALITY; LIVER; LUNG LAVAGE; MOUSE; NONHUMAN; NOSE MUCOSA; POXVIRUS; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; RISK REDUCTION; SKIN DEFECT; SMALLPOX VIRUS; SPLEEN; VACCINATION; VACCINIA VIRUS; VIRUS INFECTION; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; CELL LINE; CERCOPITHECUS AETHIOPS; FEMALE; ISOINDOLES; MICE; MICE, INBRED BALB C; ORTHOPOXVIRUS; POXVIRIDAE INFECTIONS; SMALLPOX VACCINE; VACCINIA VIRUS; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 71249115159     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00678-09     Document Type: Article

References (28)

1. Berhanu, A., R. L. Wilson, D. L. Kirkwood-Watts, D. S. King, T. K. Warren, S. A. Lund, L. L. Brown, A. K. Krupkin, E. Vandermay, W. Weimers, K. M. Honeychurch, D. W. Grosenbach, K. F. Jones, and D. E. Hruby. 2008. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J. Virol. 82:3517-3529.
2. Blasco, R., and B. Moss. 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66:4170-4179.
3. Breman, J. G., and D. A. Henderson. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308.
4. Duraffour, S., R. Snoeck, R. de Vos, J. J. van Den Oord, J. M. Crance, D. Garin, D. E. Hruby, R. Jordan, E. De Clercq, and G. Andrei. 2007. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 12:1205-1216.
5. Earl, P. L., N. Cooper, S. Wyatt, B. Moss, and M. W. Carroll. 1998. Preparation of cell cultures and vaccinia virus stocks, p. 16.16.1-16.16.13. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.), Current protocols in molecular biology, vol.2. John Wiley and Sons, Inc., New York, NY.
6. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271.
7. Grosenbach, D. W., R. Jordan, D. S. King, A. Berhanu, T. K. Warren, D. L. Kirkwood-Watts, S. Tyavanagimatt, Y. Tan, R. L. Wilson, K. F. Jones, and D. E. Hruby. 2008. Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine 26:933-946.
8. Henderson, D. A. 1999. Smallpox: clinical and epidemiologic features. Emerg. Infect. Dis. 5:537-539.
9. Huggins, J., A. Goff, L. Hensley, E. Mucker, J. Shamblin, C. Wlazlowski, W. Johnson, J. Chapman, T. Larsen, N. Twenhafel, K. Karem, I. K. Damon, C. M. Byrd, T. C. Bolken, R. Jordan, and D. Hruby. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
10. Jordan, R., A. Goff, A. Frimm, M. L. Corrado, L. E. Hensley, C. M. Byrd, E. Mucker, J. Shamblin, T. C. Bolken, C. Wlazlowski, W. Johnson, J. Chapman, N. Twenhafel, S. Tyavanagimatt, A. Amantana, J. Chinsangaram, D. E. Hruby, and J. W. Huggins. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.
11. Jordan, R., D. Tien, T. C. Bolken, K. F. Jones, S. R. Tyavanagimatt, J. Strasser, A. Frimm, M. L. Corrado, P. G. Strome, and D. E. Hruby. 2008. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 52:1721-1727.
12. Lederman, E., R. Miramontes, J. Openshaw, V. A. Olson, K. L. Karem, J. Marcinak, R. Panares, W. Staggs, D. Allen, S. G. Weber, S. Vora, S. I. Gerber, C. M. Hughes, R. Regnery, L. Collins, P. S. Diaz, M. G. Reynolds, and I. Damon. 2009. Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment. Vaccine 27:375-377.
13. Luker, K. E., M. Hutchens, T. Schultz, A. Pekosz, and G. D. Luker. 2005. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology 341:284-300.
14. Nalca, A., J. M. Hatkin, N. L. Garza, D. K. Nichols, S. W. Norris, D. E. Hruby, and R. Jordan. 2008. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 79:121-127.
15. Payne, L. G. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50:89-100.
16. Payne, L. G., and K. Kristensson. 1985. Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. J. Gen. Virol. 66: 643-646.
17. Quenelle, D. C., R. M. Buller, S. Parker, K. A. Keith, D. E. Hruby, R. Jordan, and E. R. Kern. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
18. Reading, P. C., and G. L. Smith. 2003. A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J. Gen. Virol. 84:1973-1983.
19. Roberts, K. L., and G. L. Smith. 2008. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16:472-479.
20. Sarkar, J. K., A. C. Mitra, M. K. Mukherjee, S. K. De, and D. G. Mazumdar. 1973. Virus excretion in smallpox. 1. Excretion in the throat, urine, and conjunctiva of patients. Bull. W. H. O. 48:517-522.
21. Sbrana, E., R. Jordan, D. E. Hruby, R. I. Mateo, S. Y. Xiao, M. Siirin, P. C. Newman, A. P. Da Rosa, and R. B. Tesh. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
22. Smith, G. L., B. J. Murphy, and M. Law. 2003. Vaccinia virus motility. Annu. Rev. Microbiol. 57:323-342.
23. Smith, S. K., V. A. Olson, K. L. Karem, R. Jordan, D. E. Hruby, and I. K. Damon. 2009. ST-246 in vitro efficacy against smallpox and monkeypox. Antimicrob. Agents Chemother. 53:1007-1012.
24. Talbot, T. R., E. Ziel, J. K. Doersam, B. LaFleur, S. Tollefson, and K. M. Edwards. 2004. Risk of vaccinia transfer to the hands of vaccinated persons after smallpox immunization. Clin. Infect. Dis. 38:536-541.
25. Turner, G. S. 1967. Respiratory infection of mice with vaccinia virus. J. Gen. Virol. 1:399-402.
26. Vora, S., I. Damon, V. Fulginiti, S. G. Weber, M. Kahana, S. L. Stein, S. I. Gerber, S. Garcia-Houchins, E. Lederman, D. Hruby, L. Collins, D. Scott, K. Thompson, J. V. Barson, R. Regnery, C. Hughes, R. S. Daum, Y. Li, H. Zhao, S. Smith, Z. Braden, K. Karem, V. Olson, W. Davidson, G. Trindade, T. Bolken, R. Jordan, D. Tien, and J. Marcinak. 2008. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46: 1555-1561.
27. Williamson, J. D., R. W. Reith, L. J. Jeffrey, J. R. Arrand, and M. Mackett. 1990. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J. Gen. Virol. 71:2761-2767.
28. Yang, G., D. C. Pevear, M. H. Davies, M. S. Collett, T. Bailey, S. Rippen, L. Barone, C. Burns, G. Rhodes, S. Tohan, J. W. Huggins, R. O. Baker, R. L. Buller, E. Touchette, K. Waller, J. Schriewer, J. Neyts, E. DeClercq, K. Jones, D. Hruby, and R. Jordan. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 79:13139-13149.